Tang Y, Zhang Y, Chen C, Cao Y, Wang Q, Tang C
J Cent Nerv Syst Dis. 2025; 17:11795735251322450.
PMID: 39989718
PMC: 11846125.
DOI: 10.1177/11795735251322450.
Ronat L, Rainville P, Monchi O, Hanganu A
Neurol Sci. 2025; .
PMID: 39969749
DOI: 10.1007/s10072-025-08045-6.
Winer J, Vossler H, Young C, Smith V, Romero A, Shahid-Besanti M
Brain Commun. 2025; 7(1):fcae458.
PMID: 39741783
PMC: 11686406.
DOI: 10.1093/braincomms/fcae458.
da Silva S, da Costa C, Naime A, Santos D, Farina M, Colle D
Chem Res Toxicol. 2024; 37(8):1269-1282.
PMID: 39058280
PMC: 11337211.
DOI: 10.1021/acs.chemrestox.3c00389.
Khan A, Ezeugwa J, Ezeugwu V
PLoS One. 2024; 19(3):e0293382.
PMID: 38551932
PMC: 10980241.
DOI: 10.1371/journal.pone.0293382.
Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.
Jellinger K
Int J Mol Sci. 2024; 25(1).
PMID: 38203667
PMC: 10778722.
DOI: 10.3390/ijms25010498.
Externally validated deep learning model to identify prodromal Parkinson's disease from electrocardiogram.
Karabayir I, Gunturkun F, Butler L, Goldman S, Kamaleswaran R, Davis R
Sci Rep. 2023; 13(1):12290.
PMID: 37516770
PMC: 10387090.
DOI: 10.1038/s41598-023-38782-7.
Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19.
Mancini M, Natoli S, Gardoni F, Di Luca M, Pisani A
Int J Mol Sci. 2023; 24(6).
PMID: 36982693
PMC: 10056044.
DOI: 10.3390/ijms24065618.
Morphological basis of Parkinson disease-associated cognitive impairment: an update.
Jellinger K
J Neural Transm (Vienna). 2022; 129(8):977-999.
PMID: 35726096
DOI: 10.1007/s00702-022-02522-4.
Modeling Parkinson's disease-related symptoms in alpha-synuclein overexpressing mice.
Aniszewska A, Bergstrom J, Ingelsson M, Ekmark-Lewen S
Brain Behav. 2022; 12(7):e2628.
PMID: 35652155
PMC: 9304846.
DOI: 10.1002/brb3.2628.
Glymphatic System Dysfunction in Central Nervous System Diseases and Mood Disorders.
Zhang D, Li X, Li B
Front Aging Neurosci. 2022; 14:873697.
PMID: 35547631
PMC: 9082304.
DOI: 10.3389/fnagi.2022.873697.
Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies.
Hollerhage M, Wolff A, Chakroun T, Evsyukov V, Duan L, Chua O
Mol Neurobiol. 2022; 59(7):3980-3995.
PMID: 35460053
PMC: 9167191.
DOI: 10.1007/s12035-022-02824-4.
Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson's Disease.
Behl T, Madaan P, Sehgal A, Singh S, Anwer M, Makeen H
Int J Mol Sci. 2022; 23(2).
PMID: 35054862
PMC: 8776156.
DOI: 10.3390/ijms23020678.
Thalamic white matter macrostructure and subnuclei volumes in Parkinson's disease depression.
Bhome R, Zarkali A, Thomas G, Iglesias J, Cole J, Weil R
NPJ Parkinsons Dis. 2022; 8(1):2.
PMID: 35013327
PMC: 8748828.
DOI: 10.1038/s41531-021-00270-y.
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.
Sorboni S, Moghaddam H, Jafarzadeh-Esfehani R, Soleimanpour S
Clin Microbiol Rev. 2022; 35(1):e0033820.
PMID: 34985325
PMC: 8729913.
DOI: 10.1128/CMR.00338-20.
Gut microbiota and metabolites of α-synuclein transgenic monkey models with early stage of Parkinson's disease.
Yan Y, Ren S, Duan Y, Lu C, Niu Y, Wang Z
NPJ Biofilms Microbiomes. 2021; 7(1):69.
PMID: 34475403
PMC: 8413421.
DOI: 10.1038/s41522-021-00242-3.
Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
Torres E, Stanojlovic M, Zelikowsky M, Bonsberger J, Hean S, Mulligan C
Neurobiol Dis. 2021; 158:105478.
PMID: 34390837
PMC: 8447919.
DOI: 10.1016/j.nbd.2021.105478.
The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses.
Jan A, Goncalves N, Vaegter C, Jensen P, Ferreira N
Int J Mol Sci. 2021; 22(15).
PMID: 34361100
PMC: 8347623.
DOI: 10.3390/ijms22158338.
Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies.
Ma L, Azad M, Dharmasivam M, Richardson V, Quinn R, Feng Y
Redox Biol. 2021; 41:101896.
PMID: 33799121
PMC: 8044696.
DOI: 10.1016/j.redox.2021.101896.
Do Benzodiazepines Impair Motor and Nonmotor Symptoms in a Sample of Parkinson's Disease Patients?.
Gaztanaga W, Sarno M, Margolesky J, Luca C, Singer C, Moore H
Cureus. 2021; 13(2):e13220.
PMID: 33717754
PMC: 7945787.
DOI: 10.7759/cureus.13220.